Lidoject

Lidocaine Hydrochloride, the active ingredient in Lidoject, is a local anesthetic presented as an injectable solution for intravenous and subcutaneous use. It provides temporary loss of sensation for minor surgical or diagnostic procedures and for acute pain relief in adult patients.

GNH USA supplies Lidoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable lead times, temperature‑controlled logistics, and dedicated technical support throughout the procurement process.

Lidoject is used as a local anesthetic for procedures involving the peripheral nervous system.

- Minor surgical procedures: provides localized numbness to facilitate incision and suturing - Diagnostic interventions (e.g., endoscopy, catheter placement): reduces patient discomfort during the procedure - Acute pain management: offers short‑term analgesia for severe pain episodes

Adverse reactions may occur following administration of Lidoject.

Common Side Effects: - Injection site pain - Transient tingling or numbness - Mild hypotension - Bradycardia - Nausea

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmias - Methemoglobinemia - Central nervous system toxicity (e.g., seizures)

Before using Lidoject, consider the following safety measures.

- Allergy assessment: verify no known hypersensitivity to lidocaine or amide‑type anesthetics - Cardiovascular status: monitor patients with heart block or severe conduction disorders - Dosage limits: adhere to maximum recommended dose to avoid toxicity - Concurrent CNS depressants: use caution when combined with other agents that lower seizure threshold - Pregnancy and lactation: evaluate risk‑benefit, limited data available - Store at controlled room temperature: keep in original container, protect from light and moisture

Lidoject may interact with other medicines; review the following categories.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may potentiate cardiotoxicity - Beta‑blockers (e.g., propranolol): increase risk of bradycardia and hypotension - CYP3A4 inhibitors (e.g., ketoconazole): raise plasma lidocaine levels

Moderate Interactions (Monitor Closely): - Other local anesthetics: cumulative toxicity risk - Diuretics (e.g., furosemide): may lower seizure threshold - General anesthetics (e.g., propofol): additive CNS depression